Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Alkali metal or alkaline earth containing

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424600000 - INORGANIC ACTIVE INGREDIENT CONTAINING

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20110177173COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF - A method of preventing or inhibiting L-cystine crystallization using the compounds of formula I is disclosed.07-21-2011
20080317876USE OF A MAGNESIUM ISOTOPE FOR TREATING HYPOXIA AND A MEDICAMENT COMPRISING THE SAME - The present invention describes the use of the magnetic magnesium isotope 12-25-2008
20100119624BENZISOXAZOLE MODULATORS OF D2 RECEPTOR AND/OR 5-HT2A RECEPTOR - The present invention relates to new benzisoxazole modulators of D2 receptors and/or 5-HT2A receptors, pharmaceutical compositions thereof, and methods of use thereof.05-13-2010
20100119626Genetic Markers for Assessing Risk of Developing Schizophrenia - This document provides methods and materials related to genetic markers of schizophrenia (SZ). For example, this document provides methods for using such genetic markers to assess risk of developing schizophrenia.05-13-2010
20100119625Genetic Markers of Schizophrenia Endophenotypes - This document provides methods and materials related to genetic markers of schizophrenia (SZ), schizotypal personality disorder (SPD), and/or schizoaffective disorder (SD), (collectively referred to herein as “schizophrenia spectrum disorders” or SSDs). For example, methods for using such genetic markers to identify an SSD (e.g., SZ) endophenotype are provided.05-13-2010
20100119623IMIDAZOLYL MODULATORS OF 5-HT3 RECEPTORS - The present invention relates to new imidazolyl modulators of 5-HT3 receptors, pharmaceutical compositions thereof, and methods of use thereof.05-13-2010
20130084346INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS - The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.04-04-2013
20130209586Prevention And Treatment Of Cardiac Arrhythmias - Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.08-15-2013
20130209585Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy - The presenting invention is directed to methods and compositions for the topical or transdermal treatment of neuropathy. More particularly, transdermal or topical compositions including a combination of ingredients that provide a surprising degree of effective relief from the symptoms of peripheral neuropathy and methods for administering the compositions to treat various neuropathies.08-15-2013
20100323037ANTIMICROBIAL COMPOSITION - A composition that includes ethylhexyl sulfate or a salt thereof, an alkylbenzenesulfonic acid or a salt thereof, and a carrier. The ethylhexyl sulfate, or salt thereof, and the alkylbenzenesulfonic acid, or salt thereof, are present in a weight ratio of at least about 1:2. The composition can be used for killing or inhibiting a microorganism or pathogen (e.g., bacteria, gram-negative bacteria, gram-positive bacteria, enteric bacteria, virus, fungus, mold, mildew or powdery mildew).12-23-2010
20090155390Composition and method of treating temporary and permanent hearing loss - A composition for treating permanent and temporary hearing loss includes components that function through different biological mechanisms to provide an additive effect that is equal to or greater than a sum of the effect of the individual components. The composition includes a biologically effective amount of at least one scavenger of singlet oxygen, a donor antioxidant, a third antioxidant, and a vasodilator. A method of treating hearing loss includes the step of internally administering the composition including a biologically effective amount of the at least one scavenger of singlet oxygen, the donor antioxidant, the third antioxidant, and the vasodilator to a mammal within three days of trauma to a middle or inner ear of the mammal.06-18-2009
20090155391HYDROXYCITRIC ACID SALT COMPOSITION AND METHOD OF USE FOR REDUCING BODY WEIGHT - Disclosed is a hydroxycitric acid salt composition comprising a mixture of calcium and potassium salts of hydroxycitric acid, preferably in a defined proportion. The HCA salts are prepared by a process that includes treating an aqueous extract of 06-18-2009
20100143506APPARATUS AND METHOD FOR TREATMENT OF MICROORGANISMS DURING SUGAR PRODUCTION AND SUGAR-BASED FERMENTATION PROCESSES - A method of reducing undesirable microorganism concentration in an aqueous fluid stream employed in a sugar production process or a sugar-based fermentation production process includes (a) generating ClO06-10-2010
20100003350COMPOSITION POSSESSING ANTIOXIDANT, IMMONOMODULATED, AND ANTITUMOROUS ACTION AND METHOD OF TREATING NEOPLASMS - A process retains target proteins, anti-bodies, and macromolecules (hereafter simply called “proteins”) in a hydrogel. The method employs a non-binding mechanism to trap the target proteins, yet leave them accessible to subsequent biochemical reactions.01-07-2010
20090324749Ethanolic and/or Aqueous Composition of an Ammoniacal Solution of Alkaline Metal Salts of Azide, Mainly Sodium and Potassium - The present invention consists of the discovery about an ammoniacal solution of sodium azide (NaN12-31-2009
20090304821Pharmaceutical Combination - Disclosed is a pharmaceutical combination comprising a calcium receptor modulator and a bone resorption inhibitor, wherein the calcium receptor modulator comprises a compound represented by the formula (I):12-10-2009
20090304820SOLUBILIZED BENZOYL PEROXIDE TOPICAL DRUG FORMULATION FOR THE TREATMENT OF ACNE - The invention relates to a novel solubilized benzoyl peroxide topical formulation for the treatment of acne comprising: benzoyl peroxide, one or more skin penetration enhancers, a surfactant, and one or more solvents, wherein the benzoyl peroxide is solubilized in the solvent. The invention further relates to the use of the topical formulation as well as a process for making the topical formulation.12-10-2009
20090041863Use of GSK3 inhibitors in combination with radiation therapies - The presently disclosed subject matter relates generally to the fields of molecular biology and medicine. More particularly, it concerns methods involving the use of GSK3 inhibitors in combination with radiation therapies. In some embodiments, administration of a GSK3 inhibitor to a subject results in an amelioration of cognitive decline, toxicity to vascular endothelial cells, and/or neuron death associated with radiation therapy alone.02-12-2009
20130071495INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THERAPEUTIC METHODS AND SCREENING METHOD RELATING THERETO - The present invention relates to an inhibitor of glycogen synthase kinase 3 (GSK-3) for use in a method of treating or preventing emphysema, a method of activating an emphysema cell, an activated emphysema cell obtained by this method for use in a method of treating or preventing emphysema, and a method of screening for a substance for treating or preventing emphysema.03-21-2013
20130071496CONTROLLED RELEASE COMPOSITION CONTAINING A STRONTIUM SALT - A controlled release pharmaceutical composition comprising a strontium salt. The invention also relates to the use of a strontium salt for treating a male suffering from diseases and conditions affecting metabolism and/or structural integrity of cartilage and/or bone. The invention also relates to the use of a strontium-containing compound for preventing a cartilage and/or bone condition in a subject, and for the treatment and/or prophylaxis of secondary osteoporosis.03-21-2013
20120189718MEDICINE FOR DISSOLVING AND ELIMINATING WART AND EXCRESCENCE CONSISTING OF PROTEIN AND ITS USES - A pharmaceutical composition for dissolving and eliminating wart and excrescence consisting of protein is disclosed in the present invention. The pharmaceutical composition comprises (in 100 weight parts) 1.0-60.0 parts of sodium hydroxide and/or potassium hydroxide. The pharmaceutical composition further comprises 0.25-1.0 parts of tetracaine, bufalin, venenum bufonis and/or menthol having local anesthetic effect. The pharmaceutical composition can dissolve and eliminate wart and excrescence consisting of protein immediately and has significant effect and low side effect.07-26-2012
20120195985GLYCINE TRANSPORTER-1 INHIBITORS - The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT-1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.08-02-2012
20090246297TURF MOLD REMEDIATION - A method for treating diseased plants, such as turf and trees, includes mixing a quantity of a plant remediation composition with water and applying the plant remediation composition to the diseased plants. The plant remediation composition may include from about 30 to about 50 volume percent of a potassium silicate, from about 0.25 to about 2.0 volume percent of a surfactant, from about 0.25 to about 2.0 volume percent of a polyol, and from about 46 to about 69.5 volume percent water. The plant remediation composition may be used to treat plant molds, bacteria and fungi, such as Anthracnose, Fairy Ring, Brown Patch, Dollar Spot, and Snow Mold, and may also be used to prevent and remediate insect infestations.10-01-2009
20090232910Biomarkers and therapeutics targets for cognitive decline - Enrichment of S and Z polymorphisms of alpha-1-antitrypsin (AAT) in distinct subsets of patients with cognitive disorder (pre-existing affective disorders and APOE2 allele carriers) suggests that AAT variants are potential endophenotypes for Alzheimer Disease and related disorders of cognition, behavior and affect. Such disorders include ADD/ADHD, learning disabilities, ADEM, and susceptibility to brain injury in toxic/chemical/biological/immunological events. In Alzheimer Disease, S and Z alleles affect age of onset and low AAT levels define faster progression rate. Twenty to thirty percent of all dementia patients display AAT and/or We polymorphisms. Effects of AAT may involve inflammation of liver/lung, macrophage activation and iron and lipid metabolism. AAT, its regulation, and iron metabolism represent therapeutic targets and AAT can serve as a biomarker for vulnerability and disease progression.09-17-2009
20090041862Detecting disease association with aberrant glycogen synthase kinase 3beta expression - The present invention provides a method for diagnosing a disease or disorder associated with aberrant GSK-3β expression and/or activity or for determining the predisposition of a subject to the disease or disorder. In particular, the methods of the present invention comprise detecting a marker that comprises one or more polymorphisms and/or one or more allelic variants of a glycogen synthase kinase 3β gene. The present invention also relates to a method for identifying new markers that are diagnostic of a disease or disorder associated with aberrant GSK-3β expression and/or activity. Furthermore, the present invention relates to methods of identifying and producing candidate compounds for the treatment of a disease or disorder associated with aberrant GSK-3β expression and/or activity.02-12-2009
20090081318TREATMENT OF NEUROADS USING INHIBITORS OF GLYCOGEN SYNTHASE KINASE (GSK)-3 - Provided is a method of treating or preventing neurological disease in a subject in need of such treatment or prevention, comprising administering to the subject a therapeutically effective dose of a GSK-3 inhibitor.03-26-2009
20090311347COMBINATION THERAPY FOR BIPOLAR DISORDER - Treatment regimens for mood disorders that include administration of buprenorphine, alone or in combination with additional pharmacological agents are described. Specifically, treatment regimens that alleviate racing thoughts associated with bipolar disorder, and pharmaceutical compositions and kits for use therein are described. Dosing regimens, compositions, and kits including buprenorphine for treating mania associated with opioid withdrawal are also described.12-17-2009
20110008470Carrageenan modified by ion-exchange process - A composition comprises an ion-exchanged carrageenan. The carrageenan may be a traditionally extracted or neutrally extracted iota or kappa carrageenan. The ion-exchanged carrageenan has reduced gelling cation contents, reduced gelling temperature, and reduced melting temperature, as compared to its non-ion-exchanged counterpart. The ion-exchanged carrageenan may be mixed with another carrageenan to form a carrageenan product having a unique gelling temperature and melting temperature. Also disclosed is a process for making an ion-exchanged carrageenan composition.01-13-2011
20120231092Combination Therapy for Bipolar Disorder - Treatment regimens for mood disorders that include administration of buprenorphine, alone or in combination with additional pharmacological agents are described. Specifically, treatment regimens that alleviate racing thoughts associated with bipolar disorder, and pharmaceutical compositions and kits for use therein are described. Dosing regimens, compositions, and kits including buprenorphine for treating mania associated with opioid withdrawal are also described.09-13-2012
20090142417PROCESS FOR THE PREPARATION OF CONCENTRATED SOLUTIONS OF STABILIZED HYPOBROMITES - The invention is a process for the preparation of stabilized aqueous solutions of alkali hypobromites at low temperatures, which comprises reacting a concentrated alkali hydroxide aqueous solution with bromine, and adding to the reaction product, which is a non-stabilized solution, an aqueous solution of a sulfamic compound, such as sodium sulfamate, thus forming a stabilized alkali hypobromite solution.06-04-2009
20110287114EFFERVESCENT COMPOSITION FOR FORMING A GELLED COMPOSITION, TABLET FOR FORMING A GELLED COMPOSITION, AND METHOD OF MAKING A GELLED COMPOSITION - A method of making a gelled composition that includes combining water and an effervescent tablet in a vessel, the effervescent tablet including at least 200 mg gelatin and an effervescent couple that includes an acid and a base, heating an aqueous composition (e.g., in a microwave oven), optionally adding cold water to the heated composition, and chilling the composition for a period sufficient for the composition to form a gel.11-24-2011
20110293750ACTIVATED WNT-BETA-CATENIN SIGNALING IN MELANOMA - The present invention is directed to a method of determining the prospects for survival of a melanoma patient. This method involves providing a biological sample from a patient diagnosed with melanoma, determining the level of an indicator of Wnt/β-catenin activation in the sample, comparing the level of the indicator of Wnt/β-catenin activation in the sample against a standard level of the indicator of Wnt/β-catenin activation correlated to survival of melanoma, and determining a patient's prospects for survival of melanoma based on the comparison. The present invention also relates to a method of improving survival of melanoma patients, decreasing metastases in melanoma patients, decreasing proliferation of cancer cells in melanoma patients, decreasing melanoma recurrence in melanoma patients, and/or decreasing tumor size in melanoma patients. This involves selecting melanoma patients and subsequently determining and monitoring therapy based on their level of Wnt/β-catenin activation. The selected melanoma patients are treated with a dose of an activator or synergizer of Wnt/β-catenin based on the patient's level of Wnt/β-catenin, under conditions effective, respectively, to improve survival of the selected melanoma patients, to decrease metas-tases in the selected melanoma patients, to decrease proliferation of cancer cells in the selected melanoma patients, to decrease melanoma recurrence in the selected melanoma patients, and/or to decrease tumor size in the selected melanoma patients.12-01-2011
20110014304ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS - The disclosure relates to pharmacotherapy of a psychiatric disorder which is schizophrenia and/or anxiety, wherein schizophrenia includes schizophrenia related disorders such as brief psychotic disorders, delusional disorders, schizoaffective disorders, and schizophreniform disorders, and anxiety includes panic disorders, obsessive-compulsive disorders (OCD), post-traumatic stress disorders (PTSD), social phobia or social anxiety disorders, specific phobia, and generalized anxiety disorders (GAD). The compounds of the disclosure are useful for the treatment of the above psychiatric disorders alone or in combination with other therapeutical agents effective in the treatment of schizophrenia and/or anxiety disorders.01-20-2011
20110262565PIP-2 Inhibition-Based Antiviral and Anti-Hyperlipidemic Therapies - Interaction of a specific viral domain with phosphatidylinositol 4,5-bisphosphate (PIP 2) is shown to mediate viral replication. Basic Amino Acid PIP-2 Pincer (BAAPP) domains are described herein, including, without limitation, NS5A protein of HCV, NS4B protein of HCV, poliovirus, and rhinovirus.10-27-2011
20090148541COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEBORRHEA - Methods and compositions are provided for treating dermatological diseases, disorders, and pathologies, including seborrheic dermatitis, in a subject in need thereof. In some embodiments, methods are provided for the treatment of a dermatological disease, disorder, or pathology comprising, topically administering to a subject in need of dermatological treatment a composition comprising a therapeutically effective amount of bupropion, lithium or lithium salicylate, or combinations thereof.06-11-2009
20100266714P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN - The subject invention relates to novel P2X10-21-2010
20110200687BIFEPRUNOX MESYLATE MAINTENANCE DOSE COMPOSITIONS AND METHODS FOR USING THE SAME - The present disclosure provides novel pharmaceutical dosage forms such as a maintenance treatment dose and methods for making the same, and methods for using said compounds and maintenance treatment doses to treat and prevent diseases and/or disorders.08-18-2011
20090274776Method for the Diagnosis and Treatment of Conditions Involving Aberrant Erythrocyte Potassium Levels - The present invention provides a systematic approach that allows health care providers (e.g., physicians) to use erythrocyte potassium measurements as an indicator of hypertension or risk of developing hypertension. In particular, the present invention provides systems and methods for treating conditions involving aberrant erythrocyte potassium levels (e.g., hypertension), preventing the onset of conditions involving aberrant erythrocyte potassium levels, identifying individuals at risk for developing hypertension, and evaluating the effectiveness of treatments for conditions involving aberrant erythrocyte potassium levels (e.g., hypertension).11-05-2009
20110171325Systems and Methods for Treating Pain Using Brain Stimulation - The invention comprises systems and methods for treating nociceptive pain including at least one force-regulatable device in mechanical, electrical, or chemical communication with at least one brain area identified as processing nociceptive pain signals. The force-regulatable device acts to alter the nociceptive pain signals in a brain area to alleviate nociceptive pain.07-14-2011
20110076347Molecules Interfering with Binding of Calbindin to Inositol Monophosphatase for the Treatment of Mood Disorders - This invention provides derivatives of dodecapeptide ISSIKEKYPSHS which interfere with binding of calbindin to inositol monophosphatase, and their use in treating mood disorders.03-31-2011
20100143507CARBOXYLIC ACID INHIBITORS OF HISTONE DEACETYLASE, GABA TRANSAMINASE AND SODIUM CHANNEL - The present invention relates to new carboxylic acid inhibitors of histone deacetylase, GABA transaminase, and/or sodium channel activity, pharmaceutical compositions thereof, and methods of use thereof.06-10-2010
20080311227Long-lasting mildew stain remover and method for making same - The fungi-preventative-over-time characteristic of a fungicidal metal hydrochlorite, as distinguished from the fungi-removal characteristic thereof, is greatly enhanced by adding thereto only small amounts of active fungicidal compounds selected from the group consisting of lithium hydrochlorite and iodopropynyl butyl carbamate.12-18-2008
20110206782PIPERIDINE MODULATORS OF DOPAMINE RECEPTOR - The present invention relates to new piperidine modulators of dopamine receptors, pharmaceutical compositions thereof, and methods of use thereof.08-25-2011
20110206783P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN - The subject invention relates to novel P2X08-25-2011
20080317875Inhibitor of PI3 kinase-dependent inflammatory cytokine synthesis and method for inhibiting the same - The present invention provides a novel inhibitor for inhibiting synthesis of a PI3 kinase-dependent inflammatory cytokine in vivo in a vertebrate and a method for inhibiting the same. More particularly, the present invention provides a suppressor for suppressing a cell-mediated immune response and a method for suppressing the same, as well as an activator for activating a humoral immune response and a method for activating the same. In the present invention, by administering Li ion to a living body to inhibit synthesis of an inflammatory cytokine, a cell-mediated immune responses can be suppressed, and immune-mediated inflammatory disorders (IMIDs) can be treated.12-25-2008
20090053329COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS - Combinations of 5-HT2A inverse agonists or antagonists such as pimavanserin with antipsychotics such as risperidone are shown to induce a rapid onset of antipsychotic action and increase the number of responders when compared to therapy with the antipsychotic alone. These effects can be achieved at a low dose of the antipsychotic, thereby reducing the incidence of side effects. The combinations are also effective at decreases the incidence of weight gain and increased glucose or prolactin levels caused by the antipsychotic.02-26-2009
20090081317Microbiocidal Control in the Processing of Meat-Producing Four-Legged Animals - Methods of processing four-legged slaughter animals for consumption as meat and/or meat product(s) are described. The methods comprise (I) contacting exterior surfaces of the live animal at least once when the animal is en route to being slaughtered but before it is killed by exsanguination, with a microbiocidal solution, or (II) contacting a carcass of the animal, after exsanguination, with a microbiocidal solution, or (III) contacting at least one raw meat product and/or at least one processed meat product derived from the carcass at least once with a microbiocidal solution, or (IV) conducting any two or all three of (I), (II), and (III). In each case the microbiocidal solution is, independently, comprised of: (a) water having a bromine residual derived from (i) at least one bromine source, (ii) at least one alkali metal base, and/or at least one alkaline earth metal base, and (iii) at least one halogen stabilizer; or (b) water having a bromine residual derived from (i) ammonium bromide, and/or at least one alkali metal bromide, and/or at least one alkaline earth metal bromide, and (ii) at least one alkali metal hypohalite and/or at least one alkaline earth metal hypohalite; or (c) water having a bromine residual derived from a mixture or combination of any one or more of (a) and any one or more of (b); the bromine residual in each of (a), (b), and (c) being sufficient to provide microbiocidal activity.03-26-2009
20120195984DIAGNOSIS AND TREATMENT OF THE PRODROMAL SCHIZOPHRENIC STATE - Described herein are compounds (including medical foods, pharmaceutical compositions, methods of compounding them), methods and systems for the diagnosis and/or treatment of prodromal schizophrenia. For example, described herein are methods of treating a developmentally-based neuropsychiatric disorder (schizophrenia) that includes first determining if a subject is at risk for such a disorder by examining phenotypical, serological immune markers and genotypical biomarkers. The biomarkers may be used to tailor the dose to be delivered by the medial food or pharmaceutical composition. Also described are compounds for treating prodromal (rather than full-blown) schizophrenia.08-02-2012
20110059189METHOD AND COMPOSITION FOR TREATING CANCER, EFFECTING APOPTOSIS AND TREATING RETROVIRAL INFECTIONS - A modified sodium silicate composition, and methods of treating cancer and viral infections utilizing the modified sodium silicate composition (Na03-10-2011
20090074890Substituted Triazoles as Sodium Channel Blockers - Substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, migraine, headache pain, migraine headache, epilepsy, irritable bowel syndrome, diabetic neuropathy, multiple sclerosis, manic depression and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier (I), (II), (III).03-19-2009
20090280194USE OF NITROXYL (HNO) FOR THE TREATMENT OF CANCERS OVEREXPRESSING MAT-8 - Compositions and methods for treating hormone dependent or independent cancers overexpressing MAT-8 in a patient by administration of nitroxyl-donating compounds and treating patient suffering from cancers such as prostate cancer, breast cancer, pancreatic cancer, colon cancer and lung cancer.11-12-2009
20110111062LEVODOPA PRODRUG MESYLATE, COMPOSITIONS THEREOF, AND USES THEREOF - (2R)-2-Phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parkinson's disease are provided.05-12-2011
20100303932Method for Attenuating the Effects of Botulinum Toxin - The present invention is a method for attenuating the effects of botulinum toxin poisoning using capsaicin and/or a capsaicin analog.12-02-2010
20090068290BIFEPRUNOX DOSES FOR TREATING SCHIZOPHRENIA - The present disclosure is directed to compositions, kits and methods for not only treating schizophrenia, e.g., maintaining, reducing and/or improving at least one symptom of schizophrenia, but also to achieving an absence of or a reduced presence of at least one side effect associated with schizophrenia therapy with a first-generation atypical antipsychotic.03-12-2009
20110244059INHIBITING OBESITY PROGRESSION BY INHIBITING ADIPOCYTE DIFFERENTIATION WITH A PRE-ADIPOCYTE AUTOPHAGY INHIBITOR - The present invention relates to methods of mitigating, preventing or treating weight gain or obesity in patients by administering one or more autophagy inhibitors, thereby, preventing the differentiation process of pre-adipocyte cells into a mature adipocytes. Specifically, the present invention relates to the surprising discovery that autophagy is critical for the cellular remodeling required during pre-adipocyte differentiation into mature adipocyte. By targeting and inhibiting one or more mechanisms in autophagy, adipocyte maturation is also inhibited, thus, providing a novel a pathway to prevent, mitigate and/or treat weight gain, obesity and associated diseases, such as type II diabetes.10-06-2011
20100062082ION SENSOR FOR FLUID AND METHOD FOR ITS MANUFACTURE - The invention provides a method for the measurement of a concentration of a charged species in a sample, the sample having a plurality of types of charged species and at least one insoluble component. The method comprises: providing the sample on a surface of a partly permeable layer (03-11-2010
20110104309INHIBITION OF BACTERIA THROUGH APPLICATION OF A DILUTED SOLUTION OF A SILICATE CHEMICAL - The present invention is directed to methods of inhibiting bacterial growth and reproduction. In particular, the present invention relates to methods of inhibiting bacterial growth comprising contacting bacteria with aqueous solutions of silicon.05-05-2011
200902146754-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof - The present application relates to novel 4-chromenonyl-1,4-dihydropyridinecarbonitriles, processes for their preparation, pharmaceutical compositions containing them, and their use for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.08-27-2009
20110081428Use of thioflavin-like compounds to increase life span and/or health span - The present invention provides a method of using thioflavin and functionally similar compounds to increase life span and/or health span.04-07-2011
20110070319BIFEPRUNOX DOSES FOR TREATING SCHIZOPHRENIA - The present disclosure is directed to compositions, kits and methods for not only treating schizophrenia, e.g., maintaining, reducing and/or improving at least one symptom of schizophrenia, but also to achieving an absence of or a reduced presence of at least one side effect associated with schizophrenia therapy with a first-generation atypical antipsychotic.03-24-2011
20120201908METHOD OF TREATING BIPOLAR DISORDER OR DEPRESSION USING AN ANTIESTROGEN - The disclosure provides methods of treating bipolar disorder by administering an antiestrogen to reduce the severity and frequency of mood episodes. The disclosure further provides methods of treating depression with an antiestrogen in a descending dose protocol.08-09-2012
20110151026BONE TISSUE IMPLANT COMPRISING LITHIUM IONS - The present invention is based on that local administration of lithium ions in bone tissue has been found to improve the bone formation and bone mass upon implantation of a bone tissue implant in said bone tissue.06-23-2011
20110151027STRONTIUM-DOPED CALCIUM PHOSPHATE BONE GRAFT MATERIALS - The present invention is directed to strontium-containing calcium phosphate bone graft materials. Methods of making and using the bone grafts are also described.06-23-2011
20110165269Radiation Protection System - The present invention relates to a shield for radiation attenuation. The shield includes a carrier suitable for topical application on human tissue, such as skin. The carrier includes an active ingredient that is homogenously dispersed throughout the carrier. The active ingredient includes an element suitable for attenuating radiation and having a high atomic number.07-07-2011
20110027394Cross-Linked Biopolymers, Related Compounds and Methods of Use - The present invention provides stabilized oil-in-water emulsions with an extended range of chemical, thermal and/or mechanical stabilities, and method(s) for their preparation. Such preparations provide an environmentally-protective biopolymer component exhibiting improved adherence to the dispersed phase, reducing or eliminating dissociation therefrom under such conditions, for use in the context of a range of food, pharmaceutical, personal care, health care, cosmetic and other end-use applications.02-03-2011
20110117215Microsatellite Markers of Schizophrenia - The invention includes method of determining if a subject is at risk for developing schizophrenia (SZ), schizotypal personality disorder (SPD), or schizoaffective disorder (SD).05-19-2011
20090175961Dietary Supplement Compositions - Dietary supplements are disclosed herein. For example, dietary supplements containing a combination of tripeptides, potassium, pomegranate, and passionflower are provided.07-09-2009
20110189310SMALL MOLECULE MODULATORS OF PRONGF UPTAKE - The present invention relates to a method of inhibiting cellular uptake of pro-nerve growth factor (proNGF) in a cell expressing neurotrophin p75 receptor in a mammal in need thereof. Such mammals include, for example, those suffering from neuropathological conditions. In another aspect, the invention relates to a method of promoting cellular uptake of proNGF in a cell expressing p7508-04-2011
20100068308Regulation of GSK-3alpha activity for the treatment or prevention of Alzheimer's disease - Provided is a novel use of therapeutic concentrations of an inhibitor of glycogen synthase kinase-3 (GSK-3), including lithium or any other GSK-3 inhibitor, to block, reduce or inhibit processing of amyloid precursor proteins to beta-amyloid (Aβ) peptides, which are now believed to be the principal cause of Alzheimer's disease, thereby providing methods useful for the prevention, inhibition or reversal of the disease. Also provided are methods of using agents that specifically target the α isoform of GSK-3, which is responsible for APP processing, making such selective GSK-3α-specific inhibitors especially useful in the treatment, prevention, and possible reversal of Alzheimer's disease. Further provided are kits and screening methods associated with the present methods.03-18-2010
20090081319BUFFER SOLUTIONS HAVING SELECTIVE BACTERICIDAL ACTIVITY AGAINST GRAM NEGATIVE BACTERIA AND METHODS OF USING SAME - Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided.03-26-2009
20090297635Biodisintegrable Medical Devices - According to an aspect of the present invention, the present invention provides medical devices which contain one or more polymeric regions that are at least partially biodisintegrable in bodily fluid. These devices may be implanted or inserted into a subject for treatment of various diseases, disorders and conditions.12-03-2009
20090087499DEPILATORY PRODUCT - The invention comprises a depilatory product based on a complexing gel. The product will remove the hair via reduction and hydrolysis as do chemical depilatories. Despite the peeling nature of the product, the hair is not removed by pulling it out like a wax depilatory. The product is to be applied as a single step from a component that allows the mixing of two separate parts during application to the skin. The final gel is plastic and pliable but non-mobile similar to silicone rubber. The gel should possess strength so that it can be removed from the skin as a single piece without breaking or ripping.04-02-2009
20100055207METHODS OF MAKING AND USING A LIQUID CONCENTRATE THICKENER - A process for thickening a liquid food comprises admixing an effective amount of an aqueous concentrate thickener composition with a liquid food which is capable of being thickened by a concentrate thickener composition. Preferably, the aqueous thickener concentrate is contained in a package and consists essentially of fully hydrated xanthan gum and water in a concentration suitable for thickening a portion of liquid food to facilitate its consumption by a person with dysphagia. A method of preparing the packaged aqueous concentrate thickener comprises preparing the aqueous concentrate thickener composition and packaging the aqueous concentrate thickener in packages suitable for sending the packaged aqueous concentrate thickener to a locale of a person with dysphagia.03-04-2010
20100189818SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL - Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.07-29-2010
20090291152DIBENZOTHIAZEPINE DERIVATIVES - This invention relates to novel 11-[4-[2-(2-Hydroxyethoxy)ethyl]piperazin-1-yl]dibenzo[b,f][1,4]thiazepine derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antagonists of seratonergic 5HT1A and 5HT2 receptors, dopaminergic D1 and D2 receptor, histaminergic H1 receptors, and/or adrenergic α1 and α2 receptors.11-26-2009
20120003330BENZOQUINOLONE INHIBITORS OF VMAT2 - The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.01-05-2012
20100166889METHOD OF TREATING DEPRESSIVE DISORDERS - The invention provides methods of treating depressive disorders, in particular major depression but other depressive orders also, with prodrug stimulants or analogs including amphetamine prodrugs, methylphenidate prodrugs, and methylphenidate analogs, Such methods of treatment may utilize the prodrug stimulant or analog as monotherapy or, more commonly, as an adjunct to antidepressant medication treatment to augment their effect. The invention includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered to an individual in need with one or more other active agents, either in separate forms or as a single pharmaceutical formulation. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.07-01-2010
20090258092Improved Tissue Maintenance - The invention provides a method of reducing damage to a tissue, organ or cell from surgical procedures comprising administering a composition comprising a potassium channel opener/agonist and/or an adenosine receptor agonist (eg. adenosine) together with a local anaesthetic (eg. lignocaine) when perfusing the organ.10-15-2009
20120064181P2X3 Receptor Antagonists for Treatment of Pain - The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.03-15-2012
20120121731Electrolytic System and Method for Generating Biocides Having an Electron Deficient Carrier Fluid and Chlorine Dioxide - A method for electrolytically generating a biocide having an electron deficient carrier fluid and chlorine dioxide, including providing a carrier fluid; providing a pair of electrodes interposed by a semi-permeable membrane within a vessel for creating a first passageway and a second passageway, an anode electrode of the pair of electrodes disposed in the first passageway, cathode electrode of the pair of electrodes disposed in the second passageway; flowing the carrier fluid through the vessel; applying an electric potential to the pair of electrodes to produce an oxidative acidic fluid, a reductive alkaline fluid, and anodic gases in the container; removing the fluids and gases from the vessel; mixing a portion of the anodic gases with the reductive alkaline fluid to produce a hypochlorite solution; and mixing a chlorite brine with the hypochlorite solution, followed by the introduction of additional oxidative acidic fluid to release the biocide.05-17-2012
20100247683METHODS OF IDENTIFYING POTENTIAL COMPONENTS FOR TARGETED DRUG DELIVERY COMPOSITIONS - Methods of preparing compositions for preferential distribution of active agents to injury sites are provided. The compositions may comprise a polymer with hydrophilic properties and one or more active agents, such as compounds comprising hydrophilic metal ions. Because the delivery ligand and the active agent are specifically selected so the interactions between them are mainly of an ionic nature. Methods of identifying suitable components for such compositions are also disclosed.09-30-2010
20100310681Modulation of KCNQ Potassium Channel Activity for Treatment of Psychiatric Disorders and the Symptoms Thereof - Disclosed herein are compositions and methods for treating a psychiatric disorder or symptoms thereof in a patient. The compositions comprise a compound that modulates KCNQ (Kv7) potassium channel activity and the methods include administering an effective amount of the compound that modulates KCNQ (Kv7) potassium channel activity.12-09-2010
20100173021Topical Product formulations containing strontium for reducing skin irritation - Topical formulations containing aqueous-soluble divalent strontium cation in a suitable topical keratinized skin formulation vehicle, and methods of using these formulations to inhibit skin irritation in keratinized skin, are disclosed.07-08-2010
20120321725METHODS OF PREPARING RED CLAY PROCESSED MATERIAL AND ALKALI IONIZED WATER - Provided is a method of preparing a red clay processed material using red clay and sodium hydroxide and a red clay processed material having anti-corrosive and virus disinfecting activity. Also, a method of preparing alkali ionized water having excellent anti-bacterial, virus disinfecting and anti-corrosive activity using the red clay processed material, alkali ionized water using the same, and a functional product including the same are provided. The red clay processed material and the method of preparing alkali ionized water using the same can reduce the reaction temperature and reaction time compared to a conventional process, thereby significantly reducing the production cost. The red clay processed material and the alkali ionized water have excellent anti-bacterial, anti-corrosive, and virus disinfecting activity and are not toxic, so they can be widely applied in various health-care and agricultural, livestock, and marine fields such as an agent for preventing viral infectious diseases, a food preservative, a natural agricultural pesticide or fertilizer, paint, feed, an eco-friendly construction material, a red tide/green tide inhibitor, a cosmetic additive, or an anti-corrosive agent.12-20-2012
20110293749Surgical Adjuvant Composition and Associated Methods of Use - Disclosed herein are surgical adjuvant compositions for ameliorating tissue and cellular necrosis and/or apoptosis. In addition, surgical methods are described which include the use of the adjuvant of the composition to reduce tissue and cellular necrosis and/or apoptosis.12-01-2011
20120100230Systems, Devices, and/or Methods for Managing Crops - Certain exemplary embodiments can provide a system, machine, device, manufacture, circuit, composition of matter, and/or user interface adapted for and/or resulting from, and/or a method and/or machine-readable medium comprising machine-implementable instructions for, activities that can comprise and/or relate to, applying a treatment composition comprising or derived from a molecular matrix-residing chlorine dioxide composition.04-26-2012
20080248137Magnesium-Containing Food Compositions - A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.10-09-2008
20080226752KITS OF HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE AND/OR ISOSORBIDE MONONITRATE - The present invention provides methods of treating and preventing mortality associated with heart failure in an African American patient with hypertension and improving oxygen consumption, quality of life and exercise tolerance by administering a therapeutically effective amount of at least one hydralazine compound and at least one of isosorbide dinitrate and isosorbide mononitrate, and, optionally, one or more compounds, such as, for example, a digitalis, a diuretic compound, or a compound used to treat cardiovascular diseases. In the present invention, the hydralazine compound is preferably hydralazine or a pharmaceutically acceptable salt thereof. Preferred methods of the invention comprise administering hydralazine or a pharmaceutically acceptable salt thereof and isosorbide dinitrate.09-18-2008
20130171273METHOD OF TREATING IMPAIRED WOUND HEALING IN DIABETICS - The method of treating impaired wound healing in diabetics comprises the step of administering an effective amount of a glycogen synthase kinase 3-β (GSK-3β) inhibitor to a diabetic patient in need thereof to activate the NF-E2-related factor 2 (Nrf2) and genes downstream of Nrf2 that normally regulate the expression and coordination of antioxidant responses during wound healing, but are suppressed in the diabetic patient undergoing the oxidative stress that can occur during wound healing. The GSK-3β inhibitor may be lithium or a pharmaceutically acceptable salt thereof, or TDZD-8 (4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione). The method may further comprise the step of testing the diabetic patient for the presence of oxidative stress and decreased Nrf2, which enables the early or prophylactic treatment of the patient with a GSK-3β inhibitor when the patient first presents with a wound, rather than waiting for other symptoms of impaired wound healing to occur.07-04-2013
20130149396Silicate Containing Compositions and Methods of Treatment - The present invention relates to compositions comprising a silicate and methods of use thereof. In particular, the compositions of the present invention are suitable for treating inflammatory conditions, cancer, bacterial and viral infections, and infected and uninfected wounds. The compositions of the present invention can also be useful in treating spinal cord injury, tissue remodeling, and promoting bone growth and repair.06-13-2013
20110311654METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING THE ANIMAL CENTRAL NERVOUS SYSTEM FOR PSYCHIATRIC DISORDERS - The present invention comprises methods and pharmaceutical compositions for intranasal delivery of effective amounts of DFO directly to the CNS, in particular the brain treatments that inhibit GSK3b in patients with psychiatric disorders including, but not limited to, bipolar disorder, depression, ADHD and schizophrenia. In addition a treatment composition is disclosed which comprises DFO and in certain embodiments combines DFO with one or more of the psychotropic drug types, i.e., antipsychotics, mood stabilizers and antidepressants. Moreover, a treatment for treating impairment of neural plasticity through inhibition of GSK3b is provided as well as prevention of apoptosis of cells through inhibition of GSK3b.12-22-2011
20120015052P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN - The subject invention relates to novel P2X01-19-2012
20120021074P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN - The subject invention relates to novel P2X01-26-2012
20130196002INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS - The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.08-01-2013

Patent applications in class Alkali metal or alkaline earth containing